AbCellera Results Presentation Deck

Q2 2022 BUSINESS UPDATE COPYRIGHT © ABCELLERA 7 TECHNOLOGY DEVELOPMENT. T-CELL ENGAGER PLATFORM ADVANCING NEW T-CELL ENGAGER CANCER THERAPIES Our data indicate that our CD3 panel of 200+ unique antibodies bind to a wide variety sites on the CD3 complex and is capable of constructing bispecific antibodies with a very wide range of functional activities - exactly what is needed to build tunable, optimized therapeutic T-cell engagers. CD3 + EGFR BISPECIFIC ANTIBODIES PROOF OF CONCEPT Bispecifics induced a wide range of T cell activation. Bispecifics were identified that effectively kill tumor cells with either no or very low cytokine release, suggesting these molecules could overcome key hurdles to getting into the clinic.

View entire presentation